← Leaderboards
Kartik Chandran
Albert Einstein College Of Medicine
$59,376,156
Attributed
$63,503,720
Total exposure
23
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $19M · FY2008–25$20M$15M$10M$5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$113,502,867 · 25
By mechanism
U19$81,936,424 · 10
R01$20,470,020 · 7
G20$7,100,728 · 1
R21$1,328,276 · 3
R33$1,205,486 · 1
R56$1,193,493 · 2
Top collaborators
- Jonathan R. Lai6 shared
- Jason Scott Mclellan5 shared
Most similar at Albert Einstein College Of Medicine
Same institution · by research overlap
- Jody Ye$614,940
- Mihaela Stefan-Lifshitz$1,124,599
- Jonathan R. Lai$23,560,080
- Courtney Cohen$3,541,248
- Steven Bradfute$3,407,726
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusViralInfectionGlycoproteinsCellsBaseAntibodiesDisease OutbreaksIn VivoMolecularMonoclonal AntibodiesVaccinesMediatingVirus DiseasesProteinsLeadCollaborationsHantavirusNonhuman PrimateIn VitroEngineeringViral Hemorrhagic FeversFilovirusEbola Virus
Grant awards (95)
PROVIDENT: Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics against Diverse Emerging Infectious Threats$13,987,492
U19 · FY2025 · AI · contact PI
Research Project 1: Discovery and dissection of virus-host interactions and pathogenetic mechanisms$2,360,067
U19 · FY2025 · AI · contact PI
Reverse-engineering a viral Swiss army knife: Crimean-Congo hemorrhagic fever virus glycoprotein functions in assembly, entry, and in vivo pathogenesis$585,670
R01 · FY2025 · AI · contact PI
CORE A: Administrative Core$269,097
U19 · FY2025 · AI · contact PI
Research Project 1: Discovery and dissection of virus-host interactions and pathogenetic mechanisms$171,936
U19 · FY2025 · AI · contact PI
PROVIDENT: Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics against Diverse Emerging Infectious Threats$171,936
U19 · FY2025 · AI · contact PI
PROVIDENT: Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics against Diverse Emerging Infectious Threats$40,824
U19 · FY2025 · AI · contact PI
PROVIDENT: Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics against Diverse Emerging Infectious Threats$13,946,446
U19 · FY2024 · AI · contact PI
Research Project 1: Discovery and dissection of virus-host interactions and pathogenetic mechanisms$2,708,082
U19 · FY2024 · AI · contact PI
Host-virus interactions in hantavirus glycoprotein assembly$681,755
R56 · FY2024 · AI · contact PI
Reverse-engineering a viral Swiss army knife: Crimean-Congo hemorrhagic fever virus glycoprotein functions in assembly, entry, and in vivo pathogenesis$558,501
R01 · FY2024 · AI · contact PI
CORE A: Administrative Core$447,409
U19 · FY2024 · AI · contact PI
Structure-based Vaccine Design for CCHFV$428,507
R01 · FY2024 · AI
Comprehensive genetic dissection of poxvirus membrane assembly and function$210,000
R21 · FY2024 · AI · contact PI
Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats$4,303,129
U19 · FY2023 · AI · contact PI
Project II: Biologics Engineering and Antibody Mechanism of Action$1,369,689
U19 · FY2023 · AI · contact PI
In Vivo Efficacy Testing Core$1,367,854
U19 · FY2023 · AI · contact PI
Core B: Industrialization Core$1,151,790
U19 · FY2023 · AI · contact PI
Project I: Discovery and Evaluation of Antibodies and Cocktails$1,017,092
U19 · FY2023 · AI · contact PI
Structure-based Vaccine Design for CCHFV$428,507
R01 · FY2023 · AI
Comprehensive genetic dissection of poxvirus membrane assembly and function$252,000
R21 · FY2023 · AI · contact PI
Core A: Administrative Core$238,881
U19 · FY2023 · AI · contact PI
Einstein BSL3 Laboratory Renovation to Advance Biomedical Research on RNA Viruses of Pandemic Potential$7,100,728
G20 · FY2022 · AI · contact PI
Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats$4,357,599
U19 · FY2022 · AI · contact PI
Project I: Discovery and Evaluation of Antibodies and Cocktails$1,910,034
U19 · FY2022 · AI · contact PI
Project II: Biologics Engineering and Antibody Mechanism of Action$1,910,033
U19 · FY2022 · AI · contact PI
Structure-based Vaccine Design for CCHFV$428,507
R01 · FY2022 · AI
In Vivo Efficacy Testing Core$241,658
U19 · FY2022 · AI · contact PI
Core B: Industrialization Core$218,482
U19 · FY2022 · AI · contact PI
Core A: Administrative Core$77,392
U19 · FY2022 · AI · contact PI
Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats$4,390,495
U19 · FY2021 · AI · contact PI
Project I: Discovery and Evaluation of Antibodies and Cocktails$1,745,395
U19 · FY2021 · AI · contact PI
Project II: Biologics Engineering and Antibody Mechanism of Action$1,662,068
U19 · FY2021 · AI · contact PI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics$1,084,177
R01 · FY2021 · AI · contact PI
In Vivo Efficacy Testing Core$719,499
U19 · FY2021 · AI · contact PI
Host-virus interactions in the control of filovirus entry$475,251
R01 · FY2021 · AI · contact PI
Structure-based Vaccine Design for CCHFV$428,507
R01 · FY2021 · AI
Dissecting the receptor-mediated infection mechanisms of hantaviruses$412,642
R01 · FY2021 · AI · contact PI
Core A: Administrative Core$161,732
U19 · FY2021 · AI · contact PI
Core B: Industrialization Core$101,801
U19 · FY2021 · AI · contact PI
Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats$4,452,397
U19 · FY2020 · AI · contact PI
Project II: Biologics Engineering and Antibody Mechanism of Action$1,890,899
U19 · FY2020 · AI · contact PI
Project I: Discovery and Evaluation of Antibodies and Cocktails$1,781,360
U19 · FY2020 · AI · contact PI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics$1,226,238
R01 · FY2020 · AI · contact PI
Dissecting the receptor-mediated infection mechanisms of hantaviruses$501,233
R01 · FY2020 · AI · contact PI
Host-virus interactions in the control of filovirus entry$476,065
R01 · FY2020 · AI · contact PI
Structure-based Vaccine Design for CCHFV$441,966
R01 · FY2020 · AI
In Vivo Efficacy Testing Core$396,522
U19 · FY2020 · AI · contact PI
Core A: Administrative Core$202,273
U19 · FY2020 · AI · contact PI
Core B: Industrialization Core$181,343
U19 · FY2020 · AI · contact PI
Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats$4,348,829
U19 · FY2019 · AI · contact PI
Project II: Biologics Engineering and Antibody Mechanism of Action$1,793,277
U19 · FY2019 · AI · contact PI
Project I: Discovery and Evaluation of Antibodies and Cocktails$1,694,544
U19 · FY2019 · AI · contact PI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics$1,124,111
R01 · FY2019 · AI · contact PI
Dissecting the receptor-mediated infection mechanisms of hantaviruses$741,829
R01 · FY2019 · AI · contact PI
In Vivo Efficacy Testing Core$377,221
U19 · FY2019 · AI · contact PI
Host-virus interactions in the control of filovirus entry$367,278
R01 · FY2019 · AI · contact PI
Core A: Administrative Core$290,847
U19 · FY2019 · AI · contact PI
Core B: Industrialization Core$192,940
U19 · FY2019 · AI · contact PI
Host-virus interactions in the control of filovirus entry$109,576
R01 · FY2019 · AI · contact PI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics$1,022,649
R01 · FY2018 · AI · contact PI
Mechanistic Virology Core$496,975
U19 · FY2018 · AI · contact PI
Host-virus interactions in the control of filovirus entry$478,620
R01 · FY2018 · AI · contact PI
Dissecting the receptor-mediated infection mechanisms of hantaviruses$433,121
R01 · FY2018 · AI · contact PI
Dissecting the receptor-mediated infection mechanisms of hantaviruses$321,571
R01 · FY2018 · AI · contact PI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics$189,309
R01 · FY2018 · AI · contact PI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics$1,452,650
R01 · FY2017 · AI · contact PI
Dissecting the receptor-mediated infection mechanisms of hantaviruses$766,950
R01 · FY2017 · AI · contact PI
Mechanistic Virology Core$683,529
U19 · FY2017 · AI · contact PI
Ebolavirus and marburgvirus entry into cells$511,738
R56 · FY2017 · AI · contact PI
Mechanism of receptor-mediated entry and infection by filoviruses$775,307
R01 · FY2016 · AI · contact PI
Mechanistic Virology Core$666,782
U19 · FY2016 · AI · contact PI
Discovery and evaluation of anti-filovirus therapeutics targeting NPC1$347,890
R33 · FY2016 · AI · contact PI
Mechanistic Virology Core$677,607
U19 · FY2015 · AI · contact PI
Mechanism of receptor-mediated entry and infection by filoviruses$521,419
R01 · FY2015 · AI · contact PI
Discovery and evaluation of anti-filovirus therapeutics targeting NPC1$325,000
R33 · FY2015 · AI · contact PI
Mechanism of receptor-mediated entry and infection by filoviruses$260,710
R01 · FY2015 · AI · contact PI
Discovery and evaluation of anti-filovirus therapeutics targeting NPC1$82,543
R33 · FY2015 · AI · contact PI
Mechanism of receptor-mediated entry and infection by filoviruses$784,619
R01 · FY2014 · AI · contact PI
Mechanistic Virology Core$761,167
U19 · FY2014 · AI · contact PI
Discovery and evaluation of anti-filovirus therapeutics targeting NPC1$450,053
R33 · FY2014 · AI · contact PI
Mechanisms of Ebolavirus and Marburgvirus Entry into Cells$373,749
R01 · FY2014 · AI · contact PI
Mechanisms of Ebolavirus and Marburgvirus Entry into Cells$37,101
R01 · FY2014 · AI · contact PI
Mechanism of receptor-mediated entry and infection by filoviruses$757,876
R01 · FY2013 · AI · contact PI
Mechanisms of Ebolavirus and Marburgvirus Entry into Cells$386,199
R01 · FY2013 · AI · contact PI
Discovery and evaluation of anti-filovirus therapeutics targeting NPC1$187,481
R21 · FY2013 · AI · contact PI
Mechanism of receptor-mediated entry and infection by filoviruses$852,905
R01 · FY2012 · AI · contact PI
Mechanisms of Ebolavirus and Marburgvirus Entry into Cells$410,850
R01 · FY2012 · AI · contact PI
Discovery and evaluation of anti-filovirus therapeutics targeting NPC1$224,370
R21 · FY2012 · AI · contact PI
Mechanisms of Ebolavirus and Marburgvirus Entry into Cells$410,850
R01 · FY2011 · AI · contact PI
Mechanisms of Ebolavirus and Marburgvirus Entry into Cells$415,000
R01 · FY2010 · AI · contact PI
Targets of novel Ebola virus entry inhibitors$205,425
R21 · FY2010 · AI · contact PI
Targets of novel Ebola virus entry inhibitors$249,000
R21 · FY2009 · AI · contact PI
Role of endosomal cysteine protease in Ebola and Marburg virus entry$108,000
K22 · FY2009 · AI · contact PI
Role of endosomal cysteine protease in Ebola and Marburg virus entry$160,440
K22 · FY2008 · AI · contact PI